US expands scope of Trelegy Ellipta to include asthma
Trelegy Ellipta is now the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US
Read More
Tag: Trelegy Ellipta
EU expands label of GSK/Innoviva’s COPD inhaler
The European Commission expanded the scope of GlaxoSmithKline/Innoviva’s once-daily Trelegy Ellipta to reach more patients with COPD.
Read More
GSK/Innoviva’s Trelegy Ellipta wins expanded nod for COPD
US regulators have approved GlaxoSmithKline and Innoviva’s Trelegy Ellipta to treat a wider population of chronic obstructive pulmonary disease (COPD) patients.
Read More
GSK, Innoviva seek to expand scope of Trelegy Ellipta
GlaxoSmithKline and Innoviva have submitted new data to regulators in the US in support of expanding the label of Trelegy Ellipta in chronic obstructive pulmonary disease.
Read More
GSK, Innoviva’s Trelegy Ellipta cleared for COPD
GlaxoSmithKline and Innoviva have won European approval for the novel triple therapy inhaler Trelegy Ellipta, offering a new treatment option for patients with Chronic Obstructive Pulmonary Disorder (COPD).
Read More
GSK, Innoviva announce US nod for Trelegy Ellipta
GlaxoSmithKline and Innoviva have bagged a green light in the US for the novel triple therapy inhaler Trelegy Ellipta, opening the door to a new treatment option for patients with Chronic Obstructive Pulmonary Disorder (COPD).
Read More
CHMP backs 13 treatments for EU approval
Thirteen new therapies – including two biosimilars – have been backed for approval in Europe.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
